Ovarian Cancer

CA125 Can Detect Ovarian Cancer in General Practice

Publish Date November 13, 2019

And elevated CA125 indicates higher risk for other cancers, especially in women aged ≥50 years.

Managing Anemia Associated With Olaparib for Relapsed Ovarian Cancer

By

Jiajoyce R. Conway, DNP, CRNP, AOCNP

Publish Date November 5, 2019

What are the recommendations for managing anemia in patients receiving olaparib?

Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer

By

Brian Park, PharmD

Publish Date October 25, 2019

Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

PARP Inhibitor Slows Progression of Advanced Ovarian Cancer

Publish Date October 11, 2019

Veliparib added to chemotherapy, continued as maintenance tx prolongs progression-free survival.

PTSD Symptoms Tied to Higher Risk for Ovarian Cancer

Publish Date October 8, 2019

Correlation moderately attenuated after adjustment for health and ovarian cancer risk factors.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer